TCR-engineered T cells targeting a shared β-catenin mutation eradicate solid tumors – New Study
Nature Immunology, Published online: 27 August 2025; doi:10.1038/s41590-025-02252-1
TCR-T cells are T cells engineered to express a specific T cell receptor. Here the authors present a TCR-T cell that targets CTNNB1-S37F, corresponding to a shared cancer driver mutation. This immunotherapy killed solid tumors when applied to a patient-derived xenograft model in mice.
Summary
A new immunotherapy using TCR-T cells targeting the CTNNB1-S37F cancer driver mutation shows promise in treating solid tumors. Published in Nature Immunology, the research details the development of engineered T cells expressing a specific T cell receptor (TCR) designed to recognize this shared mutation. In a patient-derived xenograft mouse model, the CTNNB1-S37F-targeted TCR-T cells effectively eradicated the tumors, suggesting a potential therapeutic strategy for cancers driven by this mutation. This offers hope for a novel and targeted approach to solid tumor treatment.
Read more…
Credits: Source
This post is part of “Science/Immunology News”, Follow for more…!!!
